NVS  Novartis Ag

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

215.0B

Vuru Grade

66.34/100

Current Price

$88.60
-0.03 (-0.03%)

Growth Price

$67.71
Overvalued by 23.58%

Stability Price

$24.64
Overvalued by 72.19%

Company Metrics

  • 22.51 P/E
  • 3.62 P/S
  • 3.06 P/B
  • 3.938 EPS
  • 13.46% Cash ROIC
  • 0.35 Cash Ratio
  • 2.719 / 3.07% Dividend
  • 1.20M Avg. Vol.
  • 2.43B Shares
  • 215.0B Market Cap.

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Novartis Takes Stake In Gamida Cell With Option To Acquire
Bidness Etc - Aug 19, 2014
Novartis AG (ADR) (NVS) has signed an agreement with Gamida Cell to invest $35 million in the Israel-based stem cell biotech company.
Novartis, Global Alliance Collaborate To Search For TB Cure
Bidness Etc - 23 hours ago
Switzerland-based Novartis AG (ADR) (NVS) signed a deal today to license its experimental drugs for the treatment of tuberculosis (TB) to the Global Alliance for TB Drug Development (TB Alliance).
Novartis' New Heart Drug Expected To Be A Hit
Bidness Etc - Aug 11, 2014
Novartis AG (ADR) (NVS) announced today that it will showcase its heart failure drug LCZ696 on August 31 at the annual meeting of the European Society of Cardiology (ESC).
Novartis AG ADR (NVS): New Analyst Report from Zacks Equity Research ...
NASDAQ - Jul 25, 2014
Novartis' second quarter results were disappointing. Core earnings per share came in at $1.34, up 7% from the year-ago period but missed the Zacks Consensus Estimate of $1.36.
Safest Dividend Stocks In The Market
ETF Daily News (blog) - Aug 18, 2014
Novartis is a perfect selection because it has a slew of pharmaceutical products and always is on the hunt for new ones. Like Merck, that means consistent and reliable cash flow, which means consistent and reliable dividends.
Novartis To Offer Stiff Competition To Amgen's Neupogen
Bidness Etc - Jul 25, 2014
Novartis AG (ADR) (NVS) announced yesterday that the Food and Drug Administration (FDA) had accepted the Biologics License Application for filgrastim by Sandoz - the generics arm of Novartis.
Active Movers - Novartis AG (ADR) (NYSE:NVS), Alkermes Plc (NASDAQ:ALKS ...
Techsonian (press release) - Aug 16, 2014
Manhattan, NY- 16 AUG, 2014 - (Techsonian) - Novartis AG (ADR) (NYSE:NVS)released thatBiotechnology stocks were among the top performers in 2012 and 2013.
Novartis AG (ADR) (NYSE:NVS) Considering To Challenge European ...
USTrade Voice - Jul 28, 2014
Dallas, Texas 07/28/2014 (ustradevoice) - Novartis AG (ADR) (NYSE:NVS) on July 25, 2014 announced that it was considering to challenge the decision of Italian and French Governments for violation of European Union regulatory framework.
Biotech Stocks With Unique Diagnostic and Therapeutic Technologies [Novartis ...
ETF Daily News - Jul 24, 2014
For example, Genentech/Roche Holding AG's (RHHBY:OTCQX) Herceptin is almost a $7 billion ($7B) global franchise, but only 20-30% of all breast cancer patients are positive for HER2 (human epidermal growth factor receptor 2), and will respond to the ...
Novartis AG Given “Neutral” Rating at Zacks (NVS)
Ticker Report - Jul 28, 2014
Novartis AG (ADR) logo Zacks restated their neutral rating on shares of Novartis AG (NYSE:NVS) in a report released on Friday.